April 30, 2018 / 1:18 PM / in 3 months

BRIEF-Johnson & Johnson's Unit Actelion Submits Supplemental New Drug Application To U.S. FDA Seeking Approval Of Opsumit

April 30 (Reuters) - Johnson & Johnson:

* ACTELION SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA SEEKING APPROVAL OF OPSUMIT® (MACITENTAN) FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)

* ACTELION PHARMACEUTICALS SAYS SUBMITS SUPPLEMENTAL NDA TO FDA FOR APPROVAL OF OPSUMIT (MACITENTAN) FOR TREATING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below